Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: Investigation using 510(k) review criteria, recommended by the Food and Drug Administration.

Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: Investigation using 510(k) review criteria, recommended by the Food and Drug Administration. by Biedenbach DJ and Jones RN published in J. Clin. Microbiol. 1996; 34 (12): 3214-3217

Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates.

Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates. by Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 24 (2): 113-116

Emerging multiply resistant enterococci among clinical isolates. II. Validation of the Etest to recognize glycopeptide-resistant strains.

Emerging multiply resistant enterococci among clinical isolates. II. Validation of the Etest to recognize glycopeptide-resistant strains. by Jones RN, Erwin ME and Anderson SC published in Diagn. Microbiol. Infect. Dis. 1995; 21 (2): 95-100

Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: A review.

Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: A review. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 22 (1-2): 19-33

Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity.

Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. by Jones RN published in J. Chemother. 1995; 7 (Suppl 2): 7-16

Canadian ofloxacin susceptibility study: A comparative study from 18 medical centers. Canadian Ofloxacin Study Group.

Canadian ofloxacin susceptibility study: A comparative study from 18 medical centers. Canadian Ofloxacin Study Group. by Hoban DJ and Jones RN. published in Chemotherapy 1995; 41 (1): 34-38

Multicenter clinical laboratory evaluation of a β-lactamase disk assay employing a novel chromogenic cephalosporin, S1.

Multicenter clinical laboratory evaluation of a β-lactamase disk assay employing a novel chromogenic cephalosporin, S1. by Doern GV, Jones RN, Gerlach EH, Washington JA, Biedenbach DJ, Brueggemann A, Erwin ME, Knapp C and Raymond J published in J. Clin. Microbiol. 1995; 33 (6): 1665-1667

Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).

Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin). by Cormican MG, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (1): 51-54

Re-evaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.

Re-evaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates. by Cormican MG and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (4): 227-230

Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam.

Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (1): 57-60